Serodus AS Issued Japanese Patent Covering ORL-1 Receptor Agonist SER100 for Isolated Systolic Hypertension
OSLO, Norway--(BUSINESS WIRE)--The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus’ proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.